Tooru (TOOR) said its operating subsidiaries are expected to deliver a strong EBITDA performance for 2025, in line with management expectations, with positive momentum carrying into the first quarter of 2026.
The branded health and wellness group said its operating businesses generated average monthly gross revenue of about £1 million in Q1 2026, alongside EBITDA of £150,000. Management expects both figures to improve further as OAF expands its market presence and Pulsin benefits from additional investment and wider distribution.
Juvela is performing in line with expectations, while OAF continues to show strong growth. The brand has launched with Asda, with initial sales ahead of expectations, and is also adding new product lines into Tesco, including Softie Sub Rolls. Meanwhile, OAF recently attended the Allergy and Free From Show in Birmingham, which the company said helped strengthen consumer and retail engagement.
Pulsin has also returned to growth following a period of consolidation and range optimisation. Tooru said new capital investment and a fresh contract manufacturing arrangement have helped improve margins, with the brand now positioned for further expansion.
Tooru is also continuing work on the proposed acquisition of Mylky, with the company exploring debt funding options to complete the deal. The proposed terms include the issue of new Tooru shares at 0.77 pence each, compared with the current share price of 0.19 pence. Management said it believes the acquisition could add meaningful scale and earnings to the group.
Tooru’s CEO Scott Livingston said: “We are seeing encouraging momentum across the Group, with strong EBITDA delivery, growing revenues and excellent progress from both Juvela and OAF. OAF's expansion into major retailers and Pulsin's return to growth demonstrate the strength of our brands and the opportunities ahead. Going forward, we firmly believe that the Group is well positioned to accelerate growth and continue building value across the portfolio. We remain excited about the opportunities in front of us as we progress through 2026.”
View from Vox
Tooru’s update points to improving operational momentum, with OAF emerging as a clear growth engine and Pulsin showing signs of recovery. If management can sustain current EBITDA levels and complete the Mylky acquisition on attractive terms, the group could enter its next phase with greater scale and stronger earnings visibility.